Clarisound rolls out mobile and tele-audiology services across Malaysia
Remote Hearing Healthcare
The company's Telecare service supports existing Clarisound customers who've completed in-person hearing tests, otoscopy, and device fitting. These foundational steps require face-to-face interaction for accuracy. Once established, Telecare bridges the gap between visits, delivering professional expertise wherever customers are.
Recognizing widespread reluctance to address hearing issues, Clarisound offers online hearing tests accessible via smartphone or computer. This discreet, minutes-long assessment provides an entry point for those uncertain about their hearing health or hesitant to seek clinical care.
Technology-Driven Accessibility
Telecare services complement in-store consultations through video appointments with qualified audiologists who evaluate, adjust, and troubleshoot remotely. This approach reduces travel time and costs while ensuring continuity for those with mobility challenges or time constraints.
'Telecare isn't a replacement, but a smart extension of personalized hearing care,' explains Kieran McCarry, Clarisound's founder. 'In-person visits remain essential for comprehensive assessments—hearing tests, ear examinations, real-ear measurements, and initial fittings. However, Telecare maintains connection between appointments, supporting aural rehabilitation with remote adjustments that fit seamlessly into daily life. This proactive approach enhances comfort and drives better long-term outcomes.'
Bridging Technology and Health
Clarisound leverages growing interest in devices like Apple AirPods Pro2 as conversation starters about hearing health. While not medical-grade substitutes, features like 'Conversation Boost' increase sound quality awareness, prompting users to seek professional advice.
Regional Impact
This model proves particularly impactful where hearing health awareness is developing. By eliminating traditional barriers—geographic distance, stigma, and clinical accessibility—Clarisound empowers individuals to address hearing health earlier and more confidently.
The integration of mobile technology, online testing, and professional telecare positions Clarisound as a Malaysian healthcare leader. Rather than treating hearing loss as niche, the company reframes it as central to everyday health. With every mobile test, teleconsultation, or hearing aid fitted, Clarisound brings hearing care out of clinical settings into daily life, where it belongs.
Hashtag: #Clarisound
The issuer is solely responsible for the content of this announcement.
About Clarisound
Clarisound is a leading hearing care provider delivering accessible, expert audiology services. Focusing on user experience and early intervention, the company combines advanced technology with professional care to support hearing health across Malaysia.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
Aethlon Medical Inc (AEMD) Q1 2026 Earnings Call Highlights: Strategic Focus on Australian ...
Release Date: August 13, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Aethlon Medical Inc (NASDAQ:AEMD) has made significant progress in its Australian oncology trial, with the first cohort of patients completing treatment without any device deficiencies or serious adverse events. The company has received formal approval from India's CDSCO to initiate an oncology trial, although they have decided to focus resources on the Australian trial for strategic reasons. Aethlon Medical Inc (NASDAQ:AEMD) has significantly reduced operating expenses by approximately 32%, primarily through payroll savings and reduced legal and consulting fees. The company is actively exploring the use of its hemo purifier for broader applications, including long COVID, and has presented promising pre-clinical data at a symposium. Aethlon Medical Inc (NASDAQ:AEMD) benefits from a 43% cash tax rebate in Australia, which helps offset research costs and makes conducting trials there financially advantageous. Negative Points The decision to not proceed with the Indian trial may delay potential strategic partnerships or regulatory approvals, as the company focuses solely on the Australian trial. Despite cost reductions, Aethlon Medical Inc (NASDAQ:AEMD) will still need to raise additional funds to continue its clinical research, as it does not yet have approved products for sale. The company faces challenges in accelerating patient enrollment in its Australian trial, although efforts are being made to address this through additional sites and recruitment strategies. The efficacy of the hemo purifier in actual clinical settings remains to be proven, as pre-clinical results may not directly translate to patient outcomes. Aethlon Medical Inc (NASDAQ:AEMD) is still in the early stages of its clinical trials, and it may take time to gather sufficient data to inform dosing and treatment effects. Q & A Highlights Warning! GuruFocus has detected 2 Warning Sign with AEMD. Q: Can you confirm if the primary endpoint of the Australian study is safety, and if the first cohort has shown no adverse events related to the hemo purifier treatment? A: Yes, the primary endpoint is safety. We have successfully passed the first cohort with no adverse events, and an independent data safety monitoring board has recommended moving forward to the second cohort. (Dr. Steven La Rosa, Chief Medical Officer) Q: The pre-clinical data showed a 98.5% removal of extracellular vesicles in a simulated treatment. Should we expect similar results in the clinical study with actual patients? A: Laboratory results often differ from clinical outcomes. The true test will be the reduction observed in actual patients, and we hope to have data from the first cohort soon. (Dr. Steven La Rosa, Chief Medical Officer) Q: With the decision not to proceed with the Indian trial, what does this mean for your cash needs and strategic focus? A: We will need to continue raising funds, ideally with strategic partners. The decision to halt the Indian trial was more about avoiding delays in approval processes rather than cost savings. (Jim Frakes, CEO and CFO) Q: Are there any advantages to conducting clinical research in Australia compared to India, especially regarding costs and incentives? A: Australia offers a significant tax rebate of about 43%, which is not available in India. This rebate can make conducting research in Australia more cost-effective despite lower hospital costs in India. (Jim Frakes, CEO and CFO) Q: What efforts are being made to accelerate patient enrollment in the Australian trial? A: We are actively working on several initiatives, including pre-screening logs, recruiting additional sites, and using clinical trial liaisons and social media campaigns to speed up enrollment. (Dr. Steven La Rosa, Chief Medical Officer) For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
7 hours ago
- Yahoo
Why Teladoc (TDOC) Stock Is Trading Up Today
What Happened? Shares of digital medical services platform Teladoc Health (NYSE:TDOC) jumped 3.7% in the afternoon session after the company announced its acquisition of Telecare, an Australian virtual care provider, to expand its international footprint. The strategic acquisition of Telecare, an Australian virtual care provider, bolsters Teladoc's international presence, adding over 300 specialists across 30 specialties to its network. While the company stated the deal, which closed on August 8, is not expected to significantly impact its 2025 financial results, it strengthens its foothold in the Australian market where it has operated for over a decade. After the initial pop the shares cooled down to $7.59, up 4% from previous close. Is now the time to buy Teladoc? Access our full analysis report here, it's free. What Is The Market Telling Us Teladoc's shares are extremely volatile and have had 42 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 2 days ago when the stock gained 8.8% on the news that markets continued to rally as the latest inflation data reinforced expectations for a Federal Reserve rate cut as soon as September. The latest Consumer Price Index (CPI) report for July showed inflation holding steady, reinforcing market expectations that the Federal Reserve could begin cutting interest rates as soon as September. Lower interest rates generally stimulate the economy by making borrowing cheaper for consumers and businesses. This can lead to increased consumer spending and e-commerce activity, which directly benefits online retail and marketplace companies. The positive economic outlook fueled a broad-based rally, pushing the S&P 500 and Nasdaq to new record highs and lifting most growth-oriented technology stocks. Teladoc is down 20.2% since the beginning of the year, and at $7.59 per share, it is trading 47% below its 52-week high of $14.33 from February 2025. Investors who bought $1,000 worth of Teladoc's shares 5 years ago would now be looking at an investment worth $37.04. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
CNET
10 hours ago
- CNET
Ultrahuman Calls Ring Air the World's Most Accurate Ovulation-Tracking Smart Ring After New Acquisition
Ultrahuman has taken an algorithm designed for intravaginal fertility monitors and transformed it into a non-invasive, temperature-sensing feature that can track your cycle right from your finger. The wearable health tech company announced today that it acquired viO HealthTech, which created the OvuSense algorithm. Validated in 13 peer-reviewed clinical publications and backed by 15 years of clinical research, the algorithm draws on data from over 260,000 cycles collected with medical-grade sensors. It was previously used in class II intravaginal medical fertility monitors. Now, Ultrahuman has adapted that technology for wellness tracking to create its Cycle and Ovulation Pro PowerPlug for the Ring Air. In a press release, Ultrahuman said Cycle and Ovulation Pro delivers over 90% accuracy in confirming ovulation -- a level the company says makes the Air the "world's most accurate cycle-tracking smart ring." This data comes from equivalence testing that compared OvuSense and Ring AIR with a multi-hormone ovulation prediction method that tracks rises in luteinizing hormone and progesterone. Though other cycle trackers may report different ovulation confirmation rates -- for example, the Oura Ring claims 96.4% -- that data isn't directly comparable to OvuSense and Ring Air's testing due to differences in validation protocols, datasets and definitions of detection. Ultrahuman Most platforms that track menstrual cycles rely on a 28-day cycle, but Cycle and Ovulation Pro takes into consideration that 87% of people who menstruate have varying cycles due to conditions such as polycystic ovary syndrome, endometriosis, non-bleeding, thyroid disorders or irregular bleeding. "This collaboration benefits from 15 years of clinically proven women's health expertise and applies it to the world's lightest smart ring," said Mohit Kumar, Ultrahuman CEO, in the press release. "For the first time, best-in-class hardware, software and algorithms with a clinical background come together in one wellness device. Our mission is to give women cutting-edge tools to optimize their health, combining clinical technology with comfort and style to deliver the most accurate women's health tool available." Cycle and Ovulation Pro complements Ultrahuman Ring Air's existing free Cycle and Ovulation PowerPlug, which provides basic conception and cycle tracking. Using physiological patterns and temperature biomarkers passively captured by the smart ring, the Pro version can support fertility planning, offer a space for mood, symptom and behavior logging and use temperature data to suggest hidden patterns in a cycle. Known as Cycle Flags, these patterns may include early, late or absent ovulation, a short luteal phase and trends potentially linked to conditions such as PCOS or miscarriage risk. Ultrahuman While the OvuSense algorithm is FDA-cleared for intravaginal use, the adapted, non-invasive version for the Ultrahuman Ring Air was created for general wellness and isn't FDA-cleared. In other words, the Ring Air isn't a substitute for contraception or for professional medical diagnosis and treatment. For those, you should consult your health care provider. How much does Ultrahuman's Cycle and Ovulation Pro cost? Now available in the US, UK, EU, Australia and Canada, Cycle and Ovulation Pro is a premium PowerPlug in the Ultrahuman app that costs $3.99 per month or $39.99 per year. The current Cycle and Ovulation PowerPlug remains free.
